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INTRODUCTION
Postoperative intra-abdominal bleeding is associated with sig-
nificant morbidity and mortality.1 There are several hemostatic 
techniques, such as mechanical means, thermal devices, and 
topical hemostatic agents, for preventing postoperative hemor-
rhage.2-4 Since each technique has advantages and disadvan-
tages, surgeons use them selectively depending on the operation 
field situation. However, despite efforts to prevent postopera-
tive bleeding, unwanted bleeding does occur. Due to continu-
ous improvement in hemostatic techniques, nonetheless, the 
incidence of postoperative bleeding has decreased, with signifi-
cant events reported in less than 1% of surgeries.5-7
Minor postoperative bleeding likely occurs frequently, but 
goes undetected. Though this minor bleeding does not affect 
hemodynamic instability, it can cause complications, such as 
infection, inflammation, and adhesion.8 Moreover, these com-
plications may affect the recurrence of cancer in cancer sur-
gery,9,10 making reduction of blood loss during surgery an im-
portant issue.
Unlike mechanical means and thermal devices, topical he-
mostatic agents can have a hemostatic effect after surgery, as 
they remain in the intra-abdomen. Topical hemostatic agents 
are also used before completion of surgery, and several are avail-
able in a range of configurations. Among topical hemostatic 
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Guard® [inflammation, fibrosis, foreign bodies, and hemorrhage (spleen: p=0.333, 0.127, 0.751, and 1.000; liver: p=0.155, 0.751, 
1.000, and 1.000, respectively)].
Conclusion: SurgiGuard® is as effective and non-toxic as Surgicel® in achieving hemostasis after porcine abdominal surgery.
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agents, oxidized regenerated cellulose (ORC) has been in use 
for several decades. ORC conducts hemostatic action through 
blood absorption, surface interaction with platelets (PLTs) and 
proteins, and coagulation cascade activation.11 Since its intro-
duction in 1943, several commercial ORC products have been 
developed,12 and are now frequently used in most gastrointesti-
nal and non-gastrointestinal operations.13,14
A novel ORC system, SurgiGuard® (Samyang Biopharmaceu-
ticals Corp., Seoul, Korea), has received approval from the Ko-
rean FDA (product license no. 47, 30/09/2014 KFDA). The pres-
ent study was performed to evaluate the hemostatic and 
pathologic effects of SurgiGuard® in abdominal surgery using a 
reproducible and clinically relevant porcine model.
MATERIALS AND METHODS
SurgiGuard® fabric and SurgiGuard® fibrillar 
SurgiGuard® is an ORC designed to assist in the control of capil-
lary, venous, and small arterial hemorrhage. Fundamentally, it 
is almost the same material as Surgicel®. SurgiGuard® fabric is a 
densely knit material similar to Surgicel® Nu-Knit, and Surgi-
Guard® fibrillar is a soft, layered material similar to Surgicel® Fi-
brillar. Experimental animals were divided into two groups: 
Group A [Surgicel® (Ethicon, Cincinnati, OH, USA)] and Group 
B [SurgiGuard® (Samyang Biopharmaceuticals Corp.)].
Experimental animals and preoperative laboratory 
parameters
This study was approved by Yonsei University College of Medi-
cine, Institutional Animal Care and Use Committee (Approval 
No. IACUC 2015-0084). Ten female pigs (25–30 kg) (XP Bio pig 
supplies and services, Ansung, Korea) were used in the study. 
All animals were kept according to Association of Assessment 
and Accreditation of Laboratory Animal Care International 
(AAALAC) standards in the mid-large sized animal facility in 
Avison Biomedical Research Center (AAALAC accreditation 
No. 1071) with regular water and food supply under constant 
temperature (22°C) and moisture level (55%). Before surgery, 
all pigs were weighed and blood samples were taken to deter-
mine the complete blood cell count, including white blood cell 
(WBC), hemoglobin (Hb), PLT, and lymphocyte counts, C-reac-
tive protein (CRP), and liver profiles, including aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), total pro-
tein, albumin, alkaline phosphatase, and total bilirubin.
Surgery preparation
Anesthesia was induced with Zoletil® (Grovet, Utrecht, the Neth-
erlands) and Rompun® (Bayer, Santa Ana, CA, USA), and the 
hair in the surgical region (upper abdomen) was removed. En-
dotracheal intubation was performed and anesthesia was 
maintained by isoflurane inhalation. The pigs were monitored 
during the procedure by pulse and oxygen saturation. The sur-
gical region was disinfected with povidone iodine, followed by 
the opening of the upper abdominal cavity for liver and spleen 
exposure.
Spleen wedge resection
After exposure of the spleen, resection points were marked on 
each side at 6 and 12 cm proximal to the distal end of the 
spleen. Parenchymal wedge resection of the spleen was per-
formed using Mayo scissors. The resected volume was 1×1 cm 
at each site. The ORC (either Surgicel® or SurgiGuard®) was 
then applied to the resection margin and covered by a cotton 
gauze sheet, and the resected spleen was weighed.
Blood loss was measured at the time of the exposure of the 
resection margin. Blood loss was measured three times for 9 
minutes after the resection. The 1st period was up to 5 minutes 
after resection, the 2nd between 5 and 7 minutes, and the 3rd 
between 7 and 9 minutes. For each period, the cotton gauze 
sheet and ORC were weighed and exchanged for new ones. If 
complete hemostasis was not achieved after the 3rd period (at 
9 minutes after resection), a mechanical or thermal method 
was performed to stop the bleeding.
Liver wedge resection 
Parenchymal wedge resection of the liver was performed in a 
similar way to the spleen. After exposure of the liver, resection 
points were marked on the left lateral and left medial lobes. The 
resected volume was 1.5×1.5 cm at each site. Each ORC was 
then applied to the resection margin and covered by a cotton 
gauze sheet. Measurement of the resected organs and blood 
loss were performed as described in next section.
Quantification of bleeding
Bleeding was quantified as follows. One sheet of a sterilized wa-
terproof surgical drape was placed below the region of resec-
tion, and blood was absorbed by sterilized gauze immediately 
after the organ resection. The blood in the surgical field was 
also absorbed by sterilized gauze. The wet gauze was then 
weighed, and blood loss was calculated as the difference be-
tween the weight of the wet gauze and the premeasured weight 
of the dry gauze.
After quantification of blood loss, the surgical region was ar-
ranged to avoid adhesion formation with the resection margin 
of the spleen and liver. The muscle and skin were then sutured. 
The time of every procedure of the operation was recorded.
Postoperative care and follow-up laboratory 
parameters
Following surgery, the pigs were permitted to consume food 
and water as normal upon recovery from anesthesia. They were 
subsequently monitored on a regular basis once per day. If any 
abnormality was found, the type and date of occurrence and 
severity of symptoms were recorded for each abnormality. All 
pigs were weighed once per week throughout the experimental 
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period. One week after the operation, a blood sample was tak-
en to measure the same parameters that were determined pre-
operatively.
Pathology
Necropsy was performed 6 weeks after surgery. All pigs were 
fasted before necropsy for at least 12 hours. Prior to receiving 
anesthesia, another set of blood samples was obtained from each 
pig to analyze the same parameters as the preoperative sam-
ples. The animals were then deeply anesthetized with Zoletil® 
and Rompun® and euthanized by exsanguination from the ca-
rotid artery.
The resected spleens and livers were examined grossly, and 
then, resection margins of the spleens and livers were marked 
using dye and fixed in a 10% neutral formalin solution. After 2 
days, the resected spleens and livers were embedded in paraf-
fin, and microsections with a thickness of 4–5 μm were ob-
tained. Hematoxylin and eosin-stained slides were prepared, 
and the specimens were examined with an optical microscope 
and scored by an expert pathologist using the 0–4 Ehrlich and 
Hunt numerical scale as modified by Phillips, et al.15 Inflamma-
tion, foreign body reaction, fibrosis, and hemorrhage were 
graded from 0–4 as follows: 0, no evidence; 1, occasional evi-
dence; 2, light scattering; 3, abundant evidence; and 4, conflu-
ent cells or fibers.
Statistical analyses
Differences in blood loss and histopathological changes be-
tween the two groups were evaluated by the Mann-Whitney 
test adding Bonferroni’s method for correction of type I errors 
to perform pair-wise comparisons between groups. Changes in 
preoperative and postoperative laboratory parameters were 
evaluated using the Wilcoxon signed-rank test. The criterion for 
statistical significance was a p value <0.05. SPSS 20.1 software 
(IBM, Armonk, NY, USA) were used for the analyses. The data 
were presented using the nonparametric method, except where 
otherwise indicated.
RESULTS
Hemostasis during wedge resection and changes 
in laboratory parameters
There was no significant difference in the weight of the resected 
spleen and liver between the two groups. There was also no sig-
nificant difference in total blood loss between the two groups. 
Upon subgroup analysis, no significant differences in blood 
loss were found, except in the subgroup of blood loss in the 
spleen at 7–9 minutes for fabric type [Group A vs. Group B, 1.35 
g (0.85–1.94) vs. 0.81 g (0.42–1.12), p=0.043] (Fig. 1).
When preoperative laboratory parameters were compared to 
those on postoperative day (POD) 7, the PLT count was signifi-
cantly increased [preoperative vs. POD 7, 182 103/μL (72–309) 
vs. 245 103/μL (182–305), p=0.049]. However, this significant dif-
ference was not present on POD 42. On the other hand, the 
weight of the pigs significantly increased [preoperative vs. POD 
42: 27.3 kg (26.5–28.9) vs. 31.1 kg (28.2–32.7), p=0.002], and sig-
nificant differences were found for AST and ALT. Despite these 
differences, all values were within normal range (Table 1).
Necropsy and histopathological findings
No hematoma, granuloma, or severe adhesion was grossly ob-
served in any of the pigs at necropsy. Histopathological analysis 
of the spleen revealed no significant differences in inflamma-
tion, fibrosis, foreign bodies, or hemorrhage between the two 
groups in accordance with the grading system (Table 2, Figs. 2 
and 3). Similar results were found upon histopathological anal-
ysis of the liver (Table 3, Figs. 4 and 5).
DISCUSSION
The ideal topical hemostatic material should have ample he-
mostatic action and minimal tissue reactivity. It should also be 
inexpensive, biodegradable, and nonantigenic.16 Many topical 
hemostatic materials have been developed over the past several 
decades taking these parameters into account, and their clini-
cal benefits and risks have been evaluated. Since ORC was first 
developed in 1943, numerous studies in various fields have de-
scribed its hemostatic effects.11,12,14,17 Currently, ORC is used not 
only in laparotomy surgery, but also in endoscopic procedures.18 
The results of our current study are similar to these previous re-
ports.
Many protocols have been established to evaluate ORC ma-
terials.19-21 Most of these protocols, however, involve application 
of a topical hemostatic material to separate animals, introduc-
ing the possibility that the different hemostatic capacity of each 
animal could affect bleeding. In order to avoid this bias, we eval-
uated different ORCs in the same animal, and used pigs due to 
their reproducible size and similarity to human anatomy, 
which enabled us to perform several experiments. In addition, 
because blood loss and spontaneous hemostasis differs be-
tween organs, studies were carried out on both the spleen and 
liver to more accurately evaluate the hemostatic capacity of the 
ORCs.16
We found no statistically significant difference in total blood 
loss between the two groups. The only statistically significant 
difference in blood loss was in the spleen in the 7–9 minute 
subgroup of the fabric type. This result may indicate that the 
hemostatic effect of SurgiGuard® Fabric occurred earlier than 
that of Surgicel® Nu-Knit on the spleen. However, because there 
were no statistically significant differences in blood loss in other 
subgroups, we cannot state that the hemostatic effect of Surgi-
Guard® occurred earlier than Surgicel®.
Postoperative minor bleeding is rarely detected. However, it 
is important due to its relationship with complications,8 and 
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Surgicel®
SurgiGuard®
Spleen Liver
Fabric Fibril Fabric Fibril
Resected organ 
weight (mg)
p=0.436 p=0.218 p=0.853 p=0.436
 102 vs.  111  80 vs.  91  264 vs.  272  205 vs.  280
1st period
(0–5 min)
2nd period 
(5–7 min)
3rd period 
(7–9 min)
Total
(0–9 min)
10
8
6
4
2
0
*
(g)
p=0.739 p=0.971 p=0.579 p=0.780
5
4
3
2
1
0
(g)
p=0.436 p=0.853 p=0.739 p=0.720
5
4
3
2
1
0
(g)
p=0.043 p=0.912 p=0.971 p=0.780
15
12
9
6
3
0
p=0.436 p=0.971 p=0.796 p=0.905
(g)
Fig. 1. Weight of the resected organs and blood loss in accordance with time and type.
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Table 1. Changes between Preoperative and Postoperative Laboratory Parameters
Paremeter Preoperative POD 7 p value POD 42 p value
Weight 27.3 (26.5–28.9) 27.5 (26.2–29.1) 0.787 31.1 (28.2–32.7) 0.002
WBC 17.52 (12.60–20.56) 16.58 (13.97–21.36) 1.000 15.29 (12.40–15.89) 0.105
Hb 8.1 (7.1–10.9) 7.5 (7.0–8.0) 0.176 7.0 (6.3–7.7) 0.059
PLT 182 (72–309) 245 (182–305) 0.049 258 (189–315) 0.322
CRP 0.2 (0.2–0.3) 0.25 (0.2–0.3) 1.000 0.2 (0.2–0.3) 1.000
Lymphocyte 8.73 (7.35–11.09) 9.56 (6.30–10.36) 0.695 9.33 (6.95–9.72) 0.625
AST 32 (25–34) 31 (28–37) 0.426 20 (17–28) 0.023
ALT 27 (25–30) 24 (22–33) 0.682 39 (32–46) 0.027
TP 6.0 (5.5–6.4) 6.1 (5.7–6.7) 0.430 6.1 (5.7–6.4) 0.791
ALB 3.0 (2.7–3.3) 2.8 (2.5–3.1) 0.086 3.2 (3.0–3.4) 0.215
ALP 320 (236–353) 221 (174–371) 0.492 270 (207–302) 0.322
TBIL 0.1 (0.1–0.3) 0.1 (0.1–0.2) 1.000 0.1 (0.1–0.1) 0.250
POD, postoperative day; WBC, white blood cells; Hb, hemoglobin; PLT, platelet; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine amino-
transferase; TP, total protein; ALB, albumin; ALP, alkaline phosphatase; TBIL, total bilirubin. 
Table 2. Histopathological Findings of Resected Spleen
Type Finding
Surgicel® 
(n=10)
SurgiGuard® 
(n=10)
p 
value
Fabric
Inflammation 0.481
G=0 9 7
G=1 1 3
G≥2 0 0
Fibrosis 0.063
G=0 1 5
G=1 7 5
G≥2 2 0
Foreign body reaction 0.280
G=0 5 8
G=1 5 2
G≥2 0 0
Hemorrhage 0.739
G=0 8 7
G=1 2 3
G≥2 0 0
Fibril
Inflammation 0.481
G=0 5 3
G=1 5 7
G≥2 0 0
Fibrosis 0.218
G=0 1 2
G=1 6 8
G≥2 3 0
Foreign body reaction 0.912
G=0 5 4
G=1 4 6
G≥2 1 0
Hemorrhage 0.739
G=0 9 10
G=1 1 0
G≥2 0 0
Table 3. Histopathological Findings of Resected Liver
Type Finding
Surgicel® 
(n=10)
SurgiGuard® 
(n=10)
p
value
Fabric
Inflammation 0.280
G=0 9 6
G=1 1 4
G≥2 0 0
Fibrosis 0.393
G=0 5 7
G=1 4 3
G≥2 1 0
Foreign body reaction 0.631
G=0 7 6
G=1 3 3
G≥2 0 1
Hemorrhage 1.000
G=0 2 2
G=1 6 6
G≥2 2 2
Fibril
Inflammation 0.481
G=0 8 6
G=1 2 4
G≥2 0 0
Fibrosis 0.739
G=0 5 5
G=1 3 5
G≥2 2 0
Foreign body reaction 0.739
G=0 7 8
G=1 3 2
G≥2 0 0
Hemorrhage 0.165
G=0 2 3
G=1 2 5
G≥2 6 2
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Inflammation
Fibrosis
Foreign body reaction
Hemorrhage
Surgicel® Nu-Knit SurgiGuard® Fabric
Fig. 2. Microscopic findings of resected spleen surface (Fabric type, hematoxylin and eosin stain, ×100).
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Inflammation
Fibrosis
Foreign body reaction
Hemorrhage
Surgicel® Fibrillar SurgiGuard® Fibrillar
Fig. 3. Microscopic findings of resected spleen surface (Fibril type, hematoxylin and eosin stain, ×100).
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Inflammation
Fibrosis
Foreign body reaction
Hemorrhage
Surgicel® Nu-Knit SurgiGuard® Fabric
Fig. 4. Microscopic findings of resected liver surface (Fabric type, hematoxylin and eosin stain, ×100).
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Inflammation
Fibrosis
Foreign body reaction
Hemorrhage
Surgicel® Fibrillar SurgiGuard® Fibrillar
Fig. 5. Microscopic findings of resected liver surface (Fibril type, hematoxylin and eosin stain, ×100).
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ORC is also occasionally used in breast cancer surgery to pre-
vent minor bleeding for aesthetic reasons.22 In our study, we 
found no significant difference in preoperative and postopera-
tive Hb values, and no gross hematoma was detected at necrop-
sy. Upon microscopic evaluation, several specimens displayed 
evidence of hemorrhage at the resected margin. However, most 
of this hemorrhage was grade I, and there was no statistically 
significant difference between the two groups. These data sug-
gest that there is no significant difference in hemostatic capaci-
ty between the two ORCs.
As the presence of artificial materials increases susceptibility 
to inflammation and infection and is toxic to adjacent organs, 
most local hemostatic agents should not be used in an infected 
wound.23 However, due to its acidic pH, ORC is resistant to bac-
terial infection,24 and several studies have found that ORC actu-
ally prevents infection.25,26 In the current study, none of the ani-
mals exhibited significant preoperative to postoperative changes 
in WBC and CRP values, the presence of which may suggest in-
fection. Although the PLT count significantly increased on POD 
7 in this study, we believe this was due not to the toxicity of the 
material, but to temporary hyposplenism due to the impaired 
splenic function. In addition, this significance was not present 
on POD 42.27,28 Although there were also significant changes 
between preoperative and postoperative AST and ALT levels, 
these values were within the normal range, and thus not clini-
cally relevant. In addition, there was no evidence of abscesses 
or other infection-related changes found at necropsy, and se-
vere inflammation was not apparent upon microscopic evalua-
tion. Therefore, the absence of significant differences between 
the two groups suggests that SurgiGuard® is not toxic to host 
cells.
ORC dissolves promptly at various sites, with complete dis-
solution by 6 weeks,12,29 which is particularly important in 
cancer surgery, because remnant ORC has occasionally been 
mistaken for abscess formation or recurrent mass.30,31 Al-
though several remnant foreign bodies were found upon mi-
croscopic examination, there were no significant differences 
between the two groups and none were observed at POD 42 
necropsy. These results suggest that SurgiGuard® has a suit-
able capacity for dissolving within a reasonable time frame.
As adhesion is the most common complication of abdominal 
surgeries, it is a concern when ORC is evaluated in abdominal 
surgery.32 Several studies have described the anti-adhesive ef-
fectiveness of ORC;33,34 Interceed® (Ethicon, Cincinnati, OH, 
USA) was developed to improve upon this aspect and is used in 
various types of surgery.35 In our study, the animals’ weight 
constantly increased, and they showed no symptoms that sug-
gested bowel obstruction. At necropsy, several pigs displayed 
minimal adhesion formation around the resected margin. 
However, it did not interfere with the necropsy, and microscop-
ic examinations showed no significant differences in fibrosis 
between the two groups.
We designed our study to use the same animal for each group 
in order to establish equivalent experimental conditions. How-
ever, a limitation of our study is the small size of the experimen-
tal groups, which potentially influenced the evaluation of statis-
tically significant outcomes. Moreover, although we strove to 
perform the wedge resection identically in each animal, there 
was an average error depending on the experimenters. Never-
theless, SurgiGuard® showed an efficacy on par with the refer-
ence material, Surgicel®, in hemostatic effects and postopera-
tive pathologic changes.
In conclusion, our study suggests that SurgiGuard® could be 
as effective and non-toxic as Surgicel® in achieving hemostasis 
after porcine spleen and liver resection. In order to overcome 
the limitations of this study, future studies should be performed 
to provide more data regarding a systemic environment, as well 
as to obtain more similar resection margins.
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